Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 9c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. SPY

Go back to Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 9c, Offers Guidance

Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results

February 10, 2016 4:02 PM EST

WASHINGTON, Feb. 10, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2015.

"2015 was a transformational year for Vanda with the continued growth of HETLIOZ in the U.S., and the European market approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "The addition of Fanapt to our U.S. product portfolio builds on this success and underscores Vanda's commitment to bringing important treatment options to patients."

Key Highlights:

HETLIOZ®... More